5 innovadores medicamentos chinos, incluyendo inhibidores de:
🧬 KRAS G12C
🧬 EGFR de tercera generación
🧬 EGFR exon 20

#Fulzerasib #Sunvozertinib #Limertinib #Glecirasib #Garsorasib #Cáncer #Oncología #TerapiaDirigida #InnovaciónMédica #KRAS
#KRASG12C #EGFR #EGFRexon20 #DengYueMedicinasEnHongKong

#Garsorasib, alone or with #Cetuximab, shows strong efficacy, manageable safety, and a favorable response in heavily pretreated #KRASG12C-mutated metastatic #ColorectalCancer, supporting improved precision therapy outcomes.

#OpenAccess in #STTT: doi.org/10.1038/s413...

China NMPA Grants Conditional Approval for Garsorasib Tablets

📩 info@dengyuemed.com
🔗https://dengyuemed.com

#ChinaNMPA #DrugApproval #Garsorasib #NSCLC #KRASG12C #InnovativeDrug #ChiataiTianqing #LungCancer

Garsorasib, a KRAS G12C inhibitor, with or without cetuximab, an EGFR antibody, in colorectal cancer cohorts of a phase II trial in advanced solid tumors with KRAS G12C mutation - Signal Transduction ... Signal Transduction and Targeted Therapy - Garsorasib, a KRAS G12C inhibitor, with or without cetuximab, an EGFR antibody, in colorectal cancer cohorts of a phase II trial in advanced solid tumors...

Phase II trial shows #KRASG12CInhibitor #Garsorasib, alone or with #cetuximab, delivers promising efficacy and manageable safety in heavily pretreated KRAS G12C–mutated #ColorectalCancer patients. #medsky

#STTT #OpenAccess: doi.org/10.1038/s413...